

**Montana Healthcare Programs Drug Utilization Review Board Agenda**  
**Hosted by Mountain Pacific Quality Health**  
**December 4, 2024**  
**1-5 PM**  
**Virtual Call Only**

Register in advance for this meeting:

<https://events.teams.microsoft.com/event/a2dacd00-f04e-410f-80b6-25ad02551b45@1f053f7a-e47d-43fd-9182-8507c9ff10c7>

1. Introductions

2. Public Comment- 15 minutes.

Public Comment will be permitted on items over which the DUR Board has jurisdiction. The public comment period will be limited to 15 minutes. All persons wishing to speak through the video conferencing platform must notify the Department by submitting their name and topic they wish to speak on via <https://forms.office.com/g/EkPyKbJYTv> by noon the day prior to the meeting. Individual comment will be limited to a maximum of 3 minutes per person but may be subject to further limitations depending on the number of speakers (15 minutes divided by total speakers).

Due to time constraints, all persons are encouraged to provide written comment, especially those providing clinical information, to allow the board adequate time to review and research. Please email written comments and/or clinical information, with a statement indicating that it is public comment, to [PDL@mt.gov](mailto:PDL@mt.gov) at least 7 days prior to the meeting. Please limit clinical information to 2 pages and to new information since last review. New peer-reviewed randomized comparative controlled trials or randomized controlled trials with true health outcomes are most helpful. Please do not provide any pricing information. Materials submitted less than 7 days prior to the meeting, in excess of 2 pages, and/or including pricing information will not be included in the board members' meeting packets.

3. Meeting Minutes

- September DUR Board

4. Department Update

5. PA Criteria updates:

- Age Extensions and Language Updates
  - Kerendia®-guideline update
- New Indication/Formulation
  - Nexletol®/Nexlizet® new indication
  - Bimzelx® new indications
  - Dupixent® new indication and age expansion
  - Leqembi® update
  - Zolgensma® update
  - Tremfya®

6. New Drugs

- Ohtuvayre®
- Ebglyss®
- Yorvipath®

7. PA Criteria removal or changes

- Jynarque® (tolvaptan)

8. Eohilia Discussion
9. Follow-up to Board's query request regarding multiple sclerosis diagnoses in members 20 years of age and younger.